Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress
This open-label trial (n=0; withdrawn) was designed to investigate the viability of ketamine-assisted psychotherapy in treating emotional distress related to cancer.
Details
Open-label, single-group early-phase study evaluating safety, feasibility, and preliminary effectiveness of three ketamine-assisted psychotherapy (KAP) sessions in patients receiving palliative radiation therapy with moderate–severe cancer-related anxiety or depression.
Each participant receives a preparatory session, three IM KAP sessions (individualised Ketalar dosing ≤60 mg or 1 mg/kg; ~3 hours per session) with a psychotherapist, and integration sessions the day after each KAP and one month after the final session.
Outcome measures include repeated assessments of depression, anxiety, and existential distress (GRID-HAM-D17, HAM-A) and feasibility/safety endpoints during and after the treatment package.